Our Latest News - BUHLMANN

BUHLMANN News

First IBD Nurse Led IBDoc Study

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Pearl Avery, UK IBD Nurse of the year, shares her first experience using IBDoc® in clinical practice. She explains the study she published at ECCO 2018 in Vienna in this video. Highlight from this Poster   "The BÜHLMANN IBDoc® adds
Continue Reading

Calprotectin Testing Goes Mobile

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article from Amanda Appleton, the Product Manager for Calprotectin at BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article     “App technology has the ability not only to improve the health of patients but
Continue Reading

IBDoc is Now Part of the TactioRPM

image credit: newswire.com US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Tactio Health Group and Telia Company team up to accelerate the development of patient-centred digital health programs in Sweden and other Nordic and Baltic countries. The Swedish telecommunication company Telia, together with AbbVie Sweden, developed the
Continue Reading

Join Us at AMLI 2018

We offer a comprehensive autoimmunity product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications.  Anti-MAG Autoantibodies ELISA  This assay is intended for the quantitative determination of human IgM-auto-antibodies directed against Myelin Associated Glycoprotein (MAG) in serum. Health Canada License: 89118 US: Research Use Only.  Not
Continue Reading

BÜHLMANN Laboratories AG Receives FDA Clearance for its fCAL® ELISA Calprotectin Test

BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. Amherst NH, June 12, 2018: BÜHLMANN Laboratories AG, is proud to announce it has received United States Food and
Continue Reading

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading

From BÜHLMANN Quantum Blue® to fCAL turbo® Follow the Evolution of Calprotectin Testing at James Cook University Hospital

Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital with SIEMENS ADVIA Chemistry XPT BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 An interview with Mr. Andrew Teggert, Clinical Scientist, James Cook University Hospital, Middlesbrough. At the largest hospital in Tees Valley,
Continue Reading

The New Biosimilar of IFX SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® IFX Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of IFX SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® IFX is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health
Continue Reading

A Pilot Study Using Point of Care Testing for IFX and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® IFX Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for IFX and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from
Continue Reading

The Clinical Utility of Basophil Activation Testing in Diagnosis and Monitoring of Allergic Disease

Chronic Urticaria and BAT Guidelines: Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, Rouzaire P, Ebo DG, Sabato V, Sanz ML, Pecaric-Petkovic T, Patil SU, Hausmann OV, Shreffler WG, Korosec P, Knol EF. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015 Nov;70(11):1393-405. Epub
Continue Reading